Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.87 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | MLNR | O43193 | 2/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | ALB | P02768 | 1/20 | 0.85 |
| ▸ | CNR1 | P21554 | 1/20 | 0.85 |
| ▸ | HTR2A | P28223 | 1/20 | 0.85 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.85 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.85 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.79 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL9011755 | 1.00 | ABCB11 (0.87) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL28498097 | 1.00 | ABCB11 (0.87) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL9011892 | 1.00 | ABCB11 (0.87) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL9011752 | 1.00 | ABCB11 (0.87) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL284867 | 0.94 | CYP3A4 (0.95) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL284866 | 0.94 | CYP3A4 (0.95) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL11319270 | 0.93 | ABCB11 (1.00) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL7597008 | 0.93 | ABCB11 (1.00) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL7597003 | 0.93 | ABCB11 (1.00) | ABCB11ABCC4CYP3A4KCNH2ABCB1 | |
| Erythromycin SCHEMBL11319266 | 0.93 | ABCB11 (1.00) | ABCB11ABCC4CYP3A4KCNH2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559098-A | Stable topical formulations with good active ingredient release characteristics, containing at least one lipophilized macrolide antibiotic | ROEHM PHARMA GMBH (DE) | 1996-09-24 | — | — | US | disclosed |
| US-5476843-A | Stable topical formulations with good active ingredient release characteristics, containing at least one lipophilized macrolide antibiotic | ROEHM PHARMA GMBH (DE) | 1995-12-19 | — | — | US | disclosed |